Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 543 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sleep Control Condition Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Sleep Plus Eating Routines for Weight Loss

NCT01717352
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Weight Loss Education, Sleep and Eating Routine
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 4 Interventional

Paroxetine in the Treatment of Chronic Primary Insomnia

NCT00178048
View directory record Official record
Conditions
Primary Insomnia, Depression
Interventions
paroxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2005 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

NCT03110315
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue, Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Controlled Trial of Mandatory Naps for Physicians in Training

NCT00874510
View directory record Official record
Conditions
Fatigue
Interventions
Mandatory Naps
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 4, 2026, 9:51 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Novel Obesity Prevention Program for High-Risk Infants in Primary Care

NCT06028113
View directory record Official record
Conditions
Obesity, Obesity, Childhood, Weight Gain, Weight Gain Trajectory
Interventions
THRIVE 2.0
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

NCT02512588
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
BTD-001, Placebo
Drug
Lead sponsor
Balance Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 3 Interventional

Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia

NCT00630175
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
zolpidem-MR (modified release), zolpidem (SL800750), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2009 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS

NCT02397057
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer, Placebo
Drug · Other
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • National City, California • Rancho Mirage, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 4, 2026, 9:51 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women

NCT07678359
View directory record Official record
Conditions
Sleep Quality, Menopause
Interventions
Lotus Seed & Rice Germ Extract, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraland USA, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL

NCT00236080
View directory record Official record
Conditions
Chronic Shift Work Sleep Disorder
Interventions
PROVIGIL 200 mg, Armodafinil 250 mg, Armodafinil 200 mg, Armodafinil 150 mg, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

NCT03037203
View directory record Official record
Conditions
Excessive Sleepiness, Parkinson Disease
Interventions
JZP-110, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Boulder, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 3 Interventional

Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.

NCT00247390
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
19
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.

NCT05015673
View directory record Official record
Conditions
Narcolepsy
Interventions
SEP363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 4, 2026, 9:51 AM EDT
Not listed Phase 2 Interventional

Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

NCT01221792
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
Columbia Northwest Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Diego, California • Lake Charles, Louisiana • Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 4, 2026, 9:51 AM EDT
Terminated Phase 3 Interventional Results available

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

NCT02829814
View directory record Official record
Conditions
Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases, Musculoskeletal Diseases
Interventions
TNX-102 SL Tablet, 2.8 mg, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Efficacy Study of EVT 201 to Treat Insomnia

NCT00380003
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
EVT 201
Drug
Lead sponsor
Evotec Neurosciences GmbH
Industry
Eligibility
21 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
St. Petersburg, Florida • Atlanta, Georgia • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Sep 4, 2026, 9:51 AM EDT
Active, not recruiting Not applicable Interventional

Auricular Acupuncture for Sleep Disturbances

NCT04956341
View directory record Official record
Conditions
Sleep Disturbance
Interventions
Auricular acupuncture, Standard treatment
Device · Other
Lead sponsor
Paul Crawford
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome

NCT00200941
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Topiramate
Drug
Lead sponsor
Neurocare
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2005 · Synced Sep 4, 2026, 9:51 AM EDT
Active, not recruiting Not applicable Interventional

Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders

NCT03540745
View directory record Official record
Conditions
Depression, Anxiety, Insomnia, Substance Abuse
Interventions
TES Treatment, TES-SHAM Treatment
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Belle Mead, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 4, 2026, 9:51 AM EDT
Recruiting Phase 2 Interventional

Cannabis for Palliative Care in Cancer

NCT06266611
View directory record Official record
Conditions
Sleep, Anxiety, Depression, Pain
Interventions
fsCBD Cannabidiol, Placebo, bsCBD Cannabidiol
Drug
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
25 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 4, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome

NCT00834327
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
aplindore MR tablets or Placebo
Drug
Lead sponsor
Neurogen Corporation
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
24
States / cities
Phoenix, Arizona • Tuscon, Arizona • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 3 Interventional

Sequential Compression Devices for Treatment of Restless Legs Syndrome

NCT00479531
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
AirCast Sequential Compression Device
Device
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Sleep Disorders Center, Walter Reed Army Medical Center, District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Sep 4, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"

NCT02348593
View directory record Official record
Conditions
Narcolepsy
Interventions
JZP-110, Placebo oral tablet
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 4, 2026, 9:51 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 4, 2026, 9:51 AM EDT